Neuroepidemiology
Original Paper
Disability and Mortality in a Cohort of Multiple Sclerosis Patients: A ReappraisalBergamaschi R.a · Montomoli C.b · Candeloro E.a · Fratti C.c · Citterio A.a · Cosi V.aaMultiple Sclerosis Centre, Department of Clinical Neurology, Neurological Institute ‘C. Mondino’, bDepartment of Health Sciences, Section of Medical Statistics and Epidemiology, University of Pavia, and cEpidemiological observatory, ASL Pavia, Pavia, Italy
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: June 06, 2005
Issue release date: June 2005
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 1
ISSN: 0251-5350 (Print)
eISSN: 1423-0208 (Online)
For additional information: https://www.karger.com/NED
Abstract
The aim of the study was to evaluate how the natural history of multiple sclerosis (MS) had changed over a 15-year period. We compared disability and mortality in a cohort of 83 MS patients hospitalised in the Neurological Institute of Pavia, northern Italy, from January 1, 1990, to December 31, 1991, with a similar cohort of 52 patients analysed in the past. After the follow-up, an unfavourable course (death or relevant disability) was observed in 41% of the patients in the new cohort, compared to 63.5% of the patients in the old one. The percentage of deceased patients was reduced from 25 to 6%. The analysis of the pooled data of the two cohorts indicates a recent tendency of firstly hospitalised patients having a shorter disease duration and a lower disability level, which could explain the relevant decrease both in mortality and disability. Finally, our findings confirmed that age at onset, early disability and a short interval between onset and secondary progression increase the risk of an unfavourable course.
© 2005 S. Karger AG, Basel
Related Articles:
References
- Citterio A, Azan G, Bergamaschi R, Erbetta A, Cosi V: Multiple sclerosis: Disability and mortality in a cohort of clinically diagnosed patients. Neuroepidemiology 1989;8:249–253.
-
McAlpine D, Lumsden CE, Acheson ED: Multiple Sclerosis: A Reappraisal. Edinburgh, Churchill Livingstone, 1972.
- Kurtzke JF: Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.
-
Clayton D, Hills M: Statistical Models in Epidemiology. Oxford, Oxford University Press, 1993.
-
Stata Corporation: Stata Statistical Software: Release 7.0. College Station, Stata, 2001.
- Myhr KM, Riise T, Vedeler C, Nortvedt MW, Gronning R, Midgard R, Nyland HI: Disability and prognosis in multiple sclerosis: Demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler 2001;7:59–65.
- Bronnum-Hansen H, Koch-Henriksen N, Stenager E: Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127:844–850.
- Weinshenker BG, Rice GPA, Noseworthy JH, Carriere W, Baskerville J, Ebers GC: The natural history of multiple sclerosis: A geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991;114:1057–1067.
- Trojano M, Avolio C, Manzari C, Calo A, De Robertis F, Serio G, Livrea P: Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995;58:300–306.
- Bergamaschi R, Berzuini C, Romani A, Cosi V: Predicting secondary progression in relapsing-remitting multiple sclerosis: A Bayesian analysis. J Neurol Sci 2001;189:13–21.
Article / Publication Details
Published online: June 06, 2005
Issue release date: June 2005
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 1
ISSN: 0251-5350 (Print)
eISSN: 1423-0208 (Online)
For additional information: https://www.karger.com/NED
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
